Table 3.

Predictors of Mayo SF subscore ≤1 and RB subscore = 0 at Week 2 in patients treated with vedolizumab

	p value	Odds ratio
		point estimate	95% CI
			lower	upper
Univariate analysis Age	0.1927	0.98	0.95	1.01
Sex (female vs. male)	0.3801	1.49	0.61	3.61
Smoker (current/ex-smoker vs. never smoked)	0.9734	0.99	0.41	2.38
UC duration	0.9796	1.00	0.93	1.07
UC duration (≥2 vs. <2 yr)	0.4690	1.61	0.44	5.80
UC duration (≥5 vs. <5 yr)	0.2549	1.74	0.67	4.49
Extraintestinal manifestations (no vs. yes)	0.5066	1.40	0.52	3.79
Disease severity based on full Mayo score (<10 vs. >10)	0.0500	0.13	0.02	1.00
Previous anti-TNFα exposure (no vs. yes)	0.0091	3.73	1.39	10.03
Anti-TNFα failure (no vs. yes)	0.0108	3.62	1.35	9.74
Corticosteroids (no vs. yes)	0.7131	0.84	0.33	2.13
Immunomodulator (no vs. yes)	0.5846	1.28	0.53	3.12
Baseline partial Mayo clinic score	<0.0001	0.38	0.24	0.60
Baseline full Mayo score	<0.0001	0.44	0.29	0.65
Baseline albumin, g/dL	0.0032	9.33	2.11	41.18
BMI	0.3525	1.06	0.94	1.20
Baseline endoscopy (moderate vs. severe)	0.2560	1.84	0.64	5.26
Baseline SF 1 versus 0	0.9613	<0.01	<0.01	>9,999.99
Baseline SF 2 versus 0	0.9678	<0.01	<0.01	>9,999.99
Baseline SF 3 versus 0	0.9934	<0.01	<0.01	>9,999.99
Baseline RB 1 versus 0	0.3758	0.60	0.19	1.87
Baseline RB 2 versus 0	0.2387	0.48	0.14	1.62
Baseline RB 3 versus 0	0.9381	<0.01	<0.01	>9,999.99
Baseline SF (non-severe vs. severe)	<0.0001	8.31	2.90	23.88
Baseline RB (non-severe vs. severe)	0.9596	>9,999.99	<0.01	>9,999.99
Disease localization (total colitis vs. left-sided colitis)	0.3447	0.65	0.27	1.58
Multivariate analysis
Previous anti-TNFα exposure (no vs. yes)	0.0252	3.32	1.16	9.50
Baseline full Mayo score	0.0001	0.44	0.29	0.67

Due to overlap between some predictors, previous anti-TNFα exposure, baseline full Mayo score, and baseline albumin were included in the multivariate analysis model. CI, confidence interval; RB, rectal bleeding; SF, stool frequency; TNFα, tumor necrosis factor alpha; UC, ulcerative colitis.